Browse by Medical Category
Contact the Medicine Innovation Program
The Medicine Innovation Program supports and enhances innovation within the Department of Medicine at Massachusetts General Hospital.
The Medicine Innovation Program (MIP) was developed as a crucial component of the Department of Medicine’s support of the culture and practice of innovation. The MIP (formerly known as the Innovation Task Force), was formed in 2015 and is charged with accelerating the development and introduction of broadly applicable innovative ideas and cost effective technologies into the patient/provider community both within and outside of Massachusetts General Hospital and the Department of Medicine - including information technology, and care delivery to device and drug approaches. The MIP is led by Director Christiana Iyasere MD, MBA and co-Director Mark Poznansky MD, PhD.
Christiana Iyasere, MD, MBA and Mark Poznansky, MD, PhD discuss the MIP Innovation Grants
In its inaugural year and following a competitive selection process for the inaugural Innovation Pilot Grant Awards, the MIP supported three projects including an early stage drug for treatment of Hypoparathyroidism, a device based therapy for urinary tract infections, and redesign of the cardiac catheterization lab patient consent process. These projects have gone on to attain follow-on grant funding, successful adoption and are transitioning through proof of concept.
MIP is proud to announce the 2017 Innovation Pilot Grant Winners and to continue to support the mission of providing funding and intensive project support to winning ideas:
Areej El-Jawahri, MD (co-sponsored by the mLab)Psychological Intervention Application (App) for Patients with Acute Myeloid Leukemia
Thomas McCoy, MDMachine Learning for Reusable Biomedical Knowledge Representation at the Bedside
Marc Wein, MD, PhDPreclinical Development of a New Osteo-Anabolic Drug to Treat Osteoporosis
Christiana Iyesere, MD, MBA is the Director of the Medicine Innovation Program. She is an established leader in the creation and implementation of platforms and projects that enhance and innovate across medicine and health care. A graduate of Yale University, Columbia University College of Physicians and Surgeons, and Harvard University Business School, Dr. Iyasere served as a Howard Hughes Research Fellow in HIV Immunology for the Laboratory of Immunoregulation at the National Institutes of Health before completing her Internal Medicine Residency at Massachusetts General Hospital and serving a year as an Administrative Fellow alongside Dr. Peter Slavin and Harry Demonaco, leading a series of projects related to optimal technology adoption and utilization. She has served in such prominent roles as Co-Director of the MGH Innovation Support Center; Associate Director of “The Sandbox,” a clinical innovation site; Technology Assessment Coordinator for the Council for Technology, Adoption, Innovation and Promotion; and Chair of the Mass General Innovation Collaborative. She is a member of the Partners Innovation Council and the Partners Epic Innovation Council. Dr. Iyasere is an Instructor of Medicine at Harvard Medical School.
Mark C. Poznansky MD, PhD is the co-Director of the Medicine Innovation Program. Dr. Poznanskyis an Associate Professor of Medicine at Harvard Medical School. He is an Attending Physician in Infectious Diseases,serves on the Commercialization Council, and isthe Director of the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital. Dr. Poznansky is the discoverer of fugetaxis, the principle of immuno-repulsion that forms the basis of the company’s products. His laboratory defines molecular mechanisms for novel immune processes and explores the relevance of these mechanisms to novel approaches to vaccines and immunotherapies for cancer, infectious diseases and diabetes. Dr. Poznansky and his team at VIC have focused on the translation of novel vaccines and immunotherapies from discovery to first-in-human studies and is funded by the JDRF, NIH, DOD and philanthropy. He is the scientific founder of a number of spinoff biotech companies including Celtaxsys and ACTx. He is also a consultant to K2 Therapeutics and was formerly a scientific consultant to Novelos and the St. Joseph’s Translational Research Institute in Atlanta.
Back to Top